Connecticut 2021 Regular Session

Connecticut Senate Bill SB00019 Latest Draft

Bill / Introduced Version Filed 01/07/2021

                             
 
LCO No. 95   	1 of 2 
 
General Assembly  Proposed Bill No. 19  
January Session, 2021  
LCO No. 95 
 
 
Referred to Committee on INSURANCE AND REAL ESTATE  
 
 
Introduced by:  
SEN. ANWAR, 3rd Dist.  
 
 
 
AN ACT CONCERNING HEALTH COVERAGE FOR OUTPATIENT 
PSYCHOTROPIC DRUGS. 
Be it enacted by the Senate and House of Representatives in General 
Assembly convened: 
 
That title 38a of the general statutes be amended to provide that no 1 
health insurance policy providing coverage for outpatient prescription 2 
drugs, or mental health care benefits provided under state law, with 3 
state funds or to state employees, shall: (1) Require a prescribing health 4 
care provider to prescribe an outpatient psychotropic drug in a quantity 5 
that the provider deems clinically inappropriate; or (2) if a prescribing 6 
health care provider deems a ninety-day supply of a covered outpatient 7 
psychotropic drug to be clinically inappropriate, impose a coinsurance, 8 
copayment, deductible or other out-of-pocket expense for the prescribed 9 
supply of such drug in an amount that exceeds the amount of the 10 
coinsurance, copayment, deductible or other out-of-pocket expense for 11 
a ninety-day supply of such drug reduced pro rata according to the 12 
quantity of the prescribed supply of such drug. 13  Proposed Bill No.  19 
 
 
LCO No. 95   	2 of 2 
 
Statement of Purpose:   
To prohibit health insurance policies providing coverage for outpatient 
prescription drugs, and mental health care benefits provided under 
state law, with state funds or to state employees, from: (1) Requiring a 
prescribing health care provider to prescribe an outpatient psychotropic 
drug in a quantity that the provider deems clinically inappropriate; or 
(2) imposing increased cost-sharing for less than a ninety-day supply of 
a covered outpatient psychotropic drug if a prescribing health care 
provider deems a ninety-day supply of such drug to be clinically 
inappropriate.